This phase II trial tests how well local ablative therapy, such as stereotactic ablative radiotherapy (SABR), hypofractionated radiation therapy, or interventional radiology (IR) ablation therapy, works in treating patients with prostate cancer, urinary tract cancer, or kidney cancer that is growing, spreading, or getting worse in a limited number of sites (oligo-progressive). SABR is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body. The total dose of radiation is divided into smaller doses given over several days. This type of radiation therapy helps spare normal tissue. Hypofractionated radiation is a type of treatment in which the total dose of radiation is divided into large doses and treatments are given less than once a day. IR ablation therapy, such as radiofrequency ablation, uses a high-frequency, electric current to kill tumor cells by heating them. IR ablation therapy, such as microwave ablation, kills tumor cells by heating them to several degrees above normal body temperature. Locally ablative therapies, such as SABR, hypofractionated radiation therapy, or IR ablation therapy, may prevent or slow progression of disease in patients with oligo-progressive prostate cancer, urinary tract cancer, or kidney cancer.
Additional locations may be listed on ClinicalTrials.gov for NCT06101290.
Locations matching your search criteria
United States
California
Chico
Enloe Medical CenterStatus: Active
Contact: Jonathan Edgar Clark
Phone: 530-332-7300
Marysville
Fremont - Rideout Cancer CenterStatus: Active
Contact: Ky Nam Bao Nguyen
Phone: 530-749-4400
Sacramento
University of California Davis Comprehensive Cancer CenterStatus: Active
Contact: Mamta Parikh
Phone: 916-734-3772
Truckee
Gene Upshaw Memorial Tahoe Forest Cancer CenterStatus: Active
Contact: Thomas John Semrad
Phone: 530-582-6450
PRIMARY OBJECTIVE:
I. To evaluate the efficacy of adding locally ablative therapies to systemic treatment regimens in patients with oligo-progressive solid tumors.
SECONDARY OBJECTIVES:
I. To evaluate the toxicities attributable to adding locally ablative therapies to systemic treatment regimens in
patients with oligoprogressive solid tumors.
II. To further evaluate the efficacy of adding locally ablative therapies to systemic treatment regimens in patients
with oligo-progressive solid tumors.
EXPLORATORY OBJECTIVE:
I. To further evaluate the efficacy of adding locally ablative therapies to systemic treatment regimens in patients with oligo-progressive solid tumors.
OUTLINE:
Patients on systemic therapy undergo local ablative therapy to up to 5 oligoprogression sites with either SABR or hypofractionated radiation over 1-15 fractions or IR ablative therapy per the treating physician's discretion on trial. Treatment continues for up to 2 months in the absence of disease progression or unacceptable toxicity. Patients also undergo computed tomography (CT) scans and/or ultrasounds on study.
After completion of study treatment, patients are followed up to 2 weeks, and then at months 3, 6, 9, 12, and 18, year 2, and up to 5 years.
Lead OrganizationUniversity of California Davis Comprehensive Cancer Center
Principal InvestigatorMamta Parikh
